K
Koji Sawada
Researcher at Hyogo College of Medicine
Publications - 68
Citations - 1676
Koji Sawada is an academic researcher from Hyogo College of Medicine. The author has contributed to research in topics: Ulcerative colitis & Medicine. The author has an hindex of 17, co-authored 56 publications receiving 1577 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study.
Takashi Shimoyama,Koji Sawada,Nobuo Hiwatashi,Toshio Sawada,Kei Matsueda,Akihiro Munakata,Hitoshi Asakura,Takao Tanaka,Reiji Kasukawa,Ken Kimura,Yasuo Suzuki,Yukio Nagamachi,Tetsuichiro Muto,Hirokazu Nagawa,Bunei Iizuka,Shozo Baba,Masaru Nasu,Tatsuji Kataoka,Nobuhito Kashiwagi,Abby R. Saniabadi +19 more
TL;DR: Based on the results, it is believed that in patients with active severe UC, patients who are refractory to conventional drugs, granulocyte and monocyte adsorption apheresis is a useful adjunct to conventional therapy.
Journal ArticleDOI
Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column.
Koji Sawada,Tetsuichiro Muto,Takashi Shimoyama,Masamichi Satomi,Toshio Sawada,Hirokazu Nagawa,Nobuo Hiwatashi,Hitoshi Asakura,Toshifumi Hibi +8 more
TL;DR: The results of the trial show that LCAP permits a reduction in total PSL dosage and is more effective and safer than high-dose PSL administration for intensive therapy, and LCAP may maintain remission longer than PSL.
Journal ArticleDOI
Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively
Hiroko Sashio,Kazuo Tamura,Reiko Ito,Yoshihiro Yamamoto,Hiroko Bamba,Tadashi Kosaka,Shin Fukui,Koji Sawada,Yoshihiro Fukuda,K. Tamura,Masamichi Satomi,Takashi Shimoyama,Jun-ichi Furuyama +12 more
TL;DR: This study suggests that one of the genes responsible for UC may be the TNF gene, or an adjacent gene, and that TNFRSF1B gene polymorphisms contribute greatly to the increased onset risk of CD and to the disease behavior.
Journal ArticleDOI
Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease.
Koji Sawada,Kunio Ohnishi,Shin Fukui,Kazuhiko Yamada,Makoto Yamamura,Kuniki Amano,K. Amano,Masaaki Wada,Noritoshi Tanida,Masamichi Satomi,Takashi Shimoyama +10 more
TL;DR: The clinical improvement in the absence of any additional medical treatment suggests that LCAP has the capacity to influence the causal mechanism(s) of IBD and that IBD is strongly associated with the cell-mediated immune response.
Journal ArticleDOI
Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.
Koji Sawada,Kazuo Kusugami,Yasuo Suzuki,Tadao Bamba,Akihiro Munakata,Toshifumi Hibi,Takashi Shimoyama +6 more
TL;DR: It is confirmed that LCAP is a safe and effective therapeutic option for patients with active UC, and the clinical activity index (CAI) value of UC indicated that the active group showed a significantly greater improvement than the sham group.